More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$370645337
EPS
0.73
P/E ratio
3.3
Price to sales
1.24
Dividend yield
--
Beta
1.479987
Previous close
$4.84
Today's open
$4.88
Day's range
$4.65 - $5.06
52 week range
$4.65 - $13.02
show more
CEO
Joseph Todisco
Employees
191
Headquarters
Parsippany, NJ
Exchange
NASDAQ Global Market
Shares outstanding
79537626
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
Zacks Investment Research • Nov 13, 2026

What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix NASDAQ: CRMD reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics' assets and deferred 2027 guidance for the dialysis treatment.
MarketBeat • Nov 12, 2026

CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.
GlobeNewsWire • Nov 12, 2026

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.
Zacks Investment Research • Nov 12, 2026

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings.
MarketBeat • Nov 10, 2026

CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
Zacks Investment Research • Nov 10, 2026

CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional consideration of up to $55 million in earn-out payments to Heron tied to calendar year 2028 ZYNRELEF net sales plus a royalty on net sales of certain products above a sales threshold Transaction expected to be immediately accretive to CorMedix earnings and free cash flow, as well as estimated to generate $45-$60 million in near-term total operating cost synergies CorMedix entered into a new senior secured term loan facility with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the transaction Heron to remain a publicly traded company with its credit facility repaid, a significant position in CorMedix common stock and rights to earn-out and royalty payments Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other customary closing conditions CorMedix to host a conference call and webcast today at 4:30 p.m. Eastern Time PARSIPPANY, N.J.
GlobeNewsWire • Nov 9, 2026

CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued at approximately $222.6 million.
Benzinga • Nov 9, 2026

CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.
GlobeNewsWire • Nov 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell CorMedix Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.